Chai Discovery and GSK announce a collaboration after a zero-shot wet-lab evaluation found binders to all tested targets

Chai Discovery announced a collaboration with GSK following a technology evaluation in which Chai's models generated designs to GSK targets zero-shot, without target-specific training, and GSK's internal wet-lab tests found binders to all tested targets. GSK gains access to Chai's platform, including its protein folding and design models, across its pipeline. Financial terms are not given. Company announcement dated 9 October 2026 (Business Wire); the results are the companies' own.